Department of Molecular and Cellular Biology, USA
Review
Docetaxel resistance in prostate cancer
Author(s): Vicky Jonathan*
Prostate cancer is one of the most common malignant tumours in the world, and it can occur as a result of genetic mutations and their accumulation when the tumour progresses to an advanced stage. Because of the absence of distinct symptoms in the early stages of prostate cancer, most cancer patients are discovered at advanced stages where tumour cells respond poorly to chemotherapy. Furthermore, genetic alterations in prostate cancer increase tumour cell aggressiveness. Docetaxel and paclitaxel are well-known drugs for prostate tumour treatment, and they have a similar role in cancer therapy that is based on preventing depolymerization of microtubules, disrupting microtubule equilibrium, and causing a delay in cell cycle progression. The current review seeks to provide insight on the mechanisms behind paclitaxel and docetaxel resistance in prostate cancer. When oncogenic factors such .. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 